S1803 Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMA

NCT04071457

Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Associated Conditions

Multiple Myeloma

Principal Investigator

Sponsor

SWOG

This study is being done to answer the following questions: (1) Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help myeloma patients survive longer?; and (2) For patients who have no evidence of myeloma in their bone marrow (patients who do not have 'minimum residual disease' [MRD-negative]), should maintenance therapy be stopped after 2 years?

This study is currently enrolling.